Amescua et al., 2024 - Google Patents
Dry eye syndrome preferred practice pattern®Amescua et al., 2024
View PDF- Document ID
- 2019337537080326009
- Author
- Amescua G
- Ahmad S
- Cheung A
- Choi D
- Jhanji V
- Lin A
- Mian S
- Rhee M
- Viriya E
- Mah F
- Varu D
- Publication year
- Publication venue
- Ophthalmology
External Links
Snippet
Dry eye syndrome (also known as dry eye disease or keratoconjunctivitis sicca) refers to a group of disorders of the tear film that are due to reduced tear production and/or tear film instability, associated with ocular discomfort and/or visual symptoms and inflammatory …
- 208000003556 Dry Eye Syndromes 0 title description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amescua et al. | Dry eye syndrome preferred practice pattern® | |
| Hieda et al. | Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study | |
| Lin et al. | Bacterial keratitis preferred practice pattern® | |
| Leung et al. | Prevalence of ocular surface disease in glaucoma patients | |
| Asbell et al. | The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee | |
| Yoo et al. | Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis | |
| Katz et al. | Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost | |
| Qiu et al. | Punctal plugs versus artificial tears for treating primary Sjögren’s syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function | |
| Zhang et al. | Vision-related quality of life and psychological status in Chinese women with Sjogren’s syndrome dry eye: a case-control study | |
| Chan et al. | Incidence and prevalence of keratoconus based on Scheimpflug imaging | |
| Miura et al. | Clinical efficacy of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: a protocol for a single-centre, randomised controlled trial | |
| Dahlmann-Noor et al. | Novel insights in the management of vernal keratoconjunctivitis (VKC): European expert consensus using a modified nominal group technique | |
| Foley et al. | Dupilumab‐associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting | |
| Bligdon et al. | Scleral lens and prosthetic replacement of the ocular surface ecosystem utilization in ocular graft-versus-host disease: a survey study | |
| Betiku et al. | Prevalence and risk factors associated with dry eye disease among adults in a population-based setting in South-West Nigeria | |
| Sakane et al. | Retrospective observational study on Rebamipide ophthalmic suspension on quality of life of dry eye disease patients | |
| Tong et al. | Conjunctival T cell profile in allogeneic hematopoietic stem cell transplant patients after instilling topical cyclosporine-A 0.1% cationic emulsion | |
| Griger et al. | Corneal involvement of patients with polymyositis and dermatomyositis | |
| Nichols et al. | Dry eye disease | |
| Salh et al. | Highlighting the Issues associated with glaucoma medication therapy: a pharmaceutical care evaluation | |
| Alamer et al. | Ophthalmic self-medication practices and associated factors of using steroid eye drops among adult ophthalmic patients | |
| Huo et al. | The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren’s syndrome related dry eye | |
| Grudzińska et al. | Macular function in patients with medium myopia | |
| Dammacco et al. | Ocular manifestations of cryoglobulinemia: a reappraisal | |
| Shimizu et al. | Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog |